Maze Therapeutics price target raised to $46 from $37 at BTIG

BTIG raised the firm’s price target on Maze Therapeutics (MAZE) to $46 from $37 and keeps a Buy rating on the shares. The firm believes the bar for success for Maze’s upcoming HORIZON data in APOL1-mediated kidney disease is “notably below” what Vertex Pharmaceuticals’ (VRTX) inaxaplin previously showed in a Phase 2 trial that only enrolled severe focal segmental glomerulosclerosis. HORIZON’s broader patient population looks more representative of the actual market that both therapies are pursuing, the analyst tells investors in a research note. BTIG likes the risk/reward for Maze shares through the HORIZON data, even considering the stock’s recent outperformance.